Could a vitamin B3 pill undo early heart damage from childhood adversity?

NCT ID NCT07073352

Recruiting now Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

This trial is taking on new participants right now.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial investigates whether a form of vitamin B3 called nicotinamide riboside (NR) can improve blood vessel function in young adults who experienced four or more adverse childhood experiences (ACEs). Researchers believe ACEs may accelerate vascular aging by lowering SIRT1, a protein that protects blood vessels, and NR may boost SIRT1 activity. The study includes young adults aged 18-30 with and without ACEs, and involves a 4-week NR supplementation period. The goal is to see if NR can restore blood vessel health and potentially reduce future heart disease risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nicotinamide riboside, a vitamin B3 derivative that boosts NAD+ levels to support SIRT1 activity
What this could lead to: If it works, this could point toward a dietary supplement that helps reverse early blood vessel damage linked to childhood adversity, potentially lowering future heart disease risk.
What could go wrong: This is a small, early proof-of-concept study. The supplement may not improve blood vessel function, and results may not apply to everyone. Side effects are possible, though NR is generally well-tolerated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 30 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 - 30 years * ACE score of 0 OR ≥4 (Aim 1); ACE score ≥4 (Aim 2) Exclusion Criteria: * Resting arterial blood pressure \>140/90 mmHg * BMI ≥30 kg/m2 and/or weight unstable (\>2.27 kg change) last 6 month * Cardiovascular, metabolic, or pulmonary disease * Cardiovascular or metabolic prescription drug use * Vasoactive antidepressant drug use (SSRIs and clonidine) * Currently pregnant or breastfeeding * Heavy alcohol consumption (AUDIT screening) * Use of illicit drugs * Current tobacco use * Regular vigorous (\>6 MET s) aerobic exercise (\>4 bouts/week, \>30 min/bout) * Dietary supplementation with antioxidants or habitual use of NSAIDs

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVERSE CHILDHOOD EXPERIENCES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVERSE CHILDHOOD EXPERIENCES ENDOTHELIAL DYSFUNCTION

Contacts and locations

Locations

Department of Kinesiology, University of Wisconsin
RECRUITING

Madison, Wisconsin, 53706, United States
Integrative Laboratory of Applied Physiology and Lifestyle Medicine
COMPLETED

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.